June 18 (Reuters) - Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

Shares of Scholar Rock jumped 13.8% in premarket trading.

Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.

Patients who took the drugs in combination also lost more fat mass than those on Zepbound alone.

Earlier this month, Regeneron said its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy.